Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + IMRT Re-Irradiation for Recurrent HNSCC
NCT03521570Phase 2Completed
- Sponsor
- Emory University
- Start
- Jun 2018
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Emory University. Started Jun 2018; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03521570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03521570.